For the year ending 2025-12-31, TVGNW had -$730,623 decrease in cash & cash equivalents over the period. -$12,393,016 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Non-cash interest expense | 0 |
| Merger transaction costs | 0 |
| Change in fair value of convertible promissory notes | 0 |
| Loss on series a preferred stock issuance | 0 |
| Loss on issuance of commitment shares | 0 |
| Stock-based compensation expense | 16,222,861 |
| Change in fair value of warrants | -60,701 |
| Amortization of right-of-use asset | 318,624 |
| Prepaid expenses and other assets | -101,838 |
| Other assets | 490,043 |
| Accounts payable | -1,964,118 |
| Accrued expenses and other liabilities | -74,203 |
| Operating lease liabilities | -297,976 |
| Depreciation expense | 190,573 |
| Net loss | -26,275,432 |
| Net cash used in operating activities | -12,328,577 |
| Purchases of property and equipment | 64,439 |
| Net cash used in investing activities | -64,439 |
| Cash acquired in connection with the reverse recapitalization | 0 |
| Proceeds from issuance of series a preferred stock | 0 |
| Proceeds from issuance of series c preferred stock | 0 |
| Nonrefundable prepaid proceeds towards anticipated series a-1 preferred stock issuance | 0 |
| Proceeds from loan agreement | 3,400,000 |
| Payment of offering costs associated with the sales agreement | 100,000 |
| Proceeds from issuance of shares under the sales agreement, net of offering costs | 4,862,393 |
| Capital contribution | 3,500,000 |
| Net cash provided by financing activities | 11,662,393 |
| Net (decrease) increase in cash | -730,623 |
| Net (decrease) increase in cash | -730,623 |
| Cash - beginning of period | 1,282,995 |
| Cash - end of period | 552,372 |
Tevogen Bio Holdings Inc. (TVGNW)
Tevogen Bio Holdings Inc. (TVGNW)